ITOC 2022 | Bispecific antibodies enable synthetic agonistic receptor T-cell therapy in melanoma

Florian Märkl, Ludwig-Maximilians-Universität München, Munich, Germany, provides an overview of a modular platform designed to target multiple antigens to tacle the challenge associated with CAR-T cells in solid tumors of tumor heterogeneity. The platform consists of T-cells armed with EGFRvIII synthetic agonistic induced receptors (SAR) in combination with bispecific antibodies. This approach can redirect SAR T-cells towards different tumor antigens and enables for reversible SAR T-cell activation. The approach was validated in murine, human and patient derived cancer models expressing the melanoma antigens TYRP1 and MCSP. This interview took place at the Immunotherapy of Cancer (ITOC) Conference 2022 in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.